Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of Immunogen Inc. (NASDAQ: IMGN) and raised his price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE